AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35210352 — intervention group
Group type: COMPARATOR
Intervention: Morning antihypertensive administration
Number of subjects: 3227
Study 35175183 — intervention group
Group type: EXPERIMENTAL
Intervention: Galileo NEO automated method
Number of subjects: 700
Study 35175183 — intervention group
Group type: COMPARATOR
Intervention: Manual CAT method
Number of subjects: 700
Study 35175183 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual DTT-treated IgG
Number of subjects: 700
Study 34887851 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU)
Number of subjects: 54
Study 34887851 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 54
Study 34887851 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) and Blank control
Number of subjects: 54
Study 35799298 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Health Intervention For Truckers (SHIFT)
Number of subjects: 382
Study 35799298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study 33646046 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple priming with the definition of DFs and information about their potentially harmful applications
Number of subjects: 0
Study 33646046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepfake recognition
Number of subjects: 0
Study 32862009 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal treatment group (tsDCS)
Number of subjects: 30
Study 32862009 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment group
Number of subjects: 30
Study 35915187 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Fundoplication (LF)
Number of subjects: 88
Study 35915187 — intervention group
Group type: COMPARATOR
Intervention: Open Fundoplication (OF)
Number of subjects: 88
Study 33865501 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab (10 mg/kg body weight for the first infusion, 20 mg/kg for subsequent infusions, administered every 3 weeks for a total of 8 infusions)
Number of subjects: 171
Study 33865501 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 171
Study 33865501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 33514774 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium animalis lactis and fructo‐oligosaccharides (FOS))
Number of subjects: 100
Study 33514774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32854693 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational device using pulsating force
Number of subjects: 28
Study 32854693 — intervention group
Group type: COMPARATOR
Intervention: Invisalign treatment (Control)
Number of subjects: 28
Study 84056285 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral diazepam and supportive care (n = 25)
Number of subjects: 50
Study 84056285 — intervention group
Group type: COMPARATOR
Intervention: Placebo and supportive care (n = 25)
Number of subjects: 50
Study 84056285 — intervention group
Group type: EXPERIMENTAL
Intervention: Further (unblinded) diazepam, 20 mg, every 1 to 2 hr for non-responders (n = 18)
Number of subjects: 50
Study 84056285 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg diazepam doses
Number of subjects: 50
Study 84056285 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the experimental phase
Number of subjects: 50
Study 35065063 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (500 mg, intramuscular)
Number of subjects: 346
Study 35065063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1000 mg, intramuscular)
Number of subjects: 346
Study 35065063 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (5 mg/kg, maximum 400 mg, intramuscular)
Number of subjects: 346
Study 35065063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (6 g, oral)
Number of subjects: 346
Study 34711192 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 2 mg/kg
Number of subjects: 344
Study 34711192 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg/kg
Number of subjects: 344
Study 34711192 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 16 mg/kg
Number of subjects: 344
Study 34711192 — intervention group
Group type: COMPARATOR
Intervention: neostigmine/glycopyrrolate
Number of subjects: 344
Study 32164494 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 6979
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered nurse/social educator
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed practical nurse
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting symptoms of psychological distress
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to leave the job
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor attitudes towards people with dementia
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor quality of childhood
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-related conflicts
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident aggression
Number of subjects: 3693
Study 33740965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of support from a manager
Number of subjects: 3693
Study 32037125 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 866
Study 32037125 — intervention group
Group type: COMPARATOR
Intervention: Non-corticosteroids
Number of subjects: 866
Study 33866311 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Number of subjects: 103
Study 33866311 — intervention group
Group type: COMPARATOR
Intervention: Sham cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Number of subjects: 103
Study 35412430 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant irinotecan-based therapy (IFL)
Number of subjects: 400
Study 35412430 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant fluorouracil/leucovorin (5‐FU/LV)
Number of subjects: 400
Study 35412430 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant irinotecan-based therapy (IFL) in patients with unDCR1 and KRAS-wildtype tumours
Number of subjects: 400
Study 35412430 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant fluorouracil/leucovorin (5‐FU/LV) in patients with unDCR1 and KRAS-wildtype tumours
Number of subjects: 400
Study 33350172 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition condition
Number of subjects: 0
Study 33350172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperation condition
Number of subjects: 0
Study 33350172 — intervention group
Group type: COMPARATOR
Intervention: Individual condition
Number of subjects: 0
Study 33350172 — intervention group
Group type: EXPERIMENTAL
Intervention: Males in competitive situation
Number of subjects: 0
Study 33350172 — intervention group
Group type: EXPERIMENTAL
Intervention: Males in cooperative situation
Number of subjects: 0
Study 32452549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 4 weeks
Number of subjects: 125
Study 32452549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 4 weeks
Number of subjects: 125
Study 32452549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks
Number of subjects: 125
Study 32452549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 32452549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab (all doses)
Number of subjects: 125
Study 35343430 — intervention group
Group type: EXPERIMENTAL
Intervention: New sodium valproate formulation (epilenil 500-mg coated tablet)
Number of subjects: 0
Study 33098330 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality game (Dreamland)
Number of subjects: 188
Study 33098330 — intervention group
Group type: COMPARATOR
Intervention: Tablet with video games (control group)
Number of subjects: 188
Study 36165607 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR assay
Number of subjects: 143
Study 36165607 — intervention group
Group type: EXPERIMENTAL
Intervention: nPCR assay
Number of subjects: 143
Study 36165607 — intervention group
Group type: EXPERIMENTAL
Intervention: VDRL test
Number of subjects: 143
Study 36165607 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot test
Number of subjects: 143
Study 36165607 — intervention group
Group type: EXPERIMENTAL
Intervention: Treponemal tests (TT)
Number of subjects: 143
Study 34030647 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 839
Study 34030647 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram for predicting CSS
Number of subjects: 839
Study 34030647 — intervention group
Group type: COMPARATOR
Intervention: AJCC staging system
Number of subjects: 839
Study 34555151 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meal pattern (14 days; 6 meals/day)
Number of subjects: 9
Study 34555151 — intervention group
Group type: COMPARATOR
Intervention: Irregular meal pattern (14 days; 3-9 meals/day)
Number of subjects: 9
Study 32198794 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 116
Study 33561724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 141
Study 33561724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 32290136 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 119
Study 32290136 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 119
Study 32290136 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength + Endurance training (SE)
Number of subjects: 119
Study 32290136 — intervention group
Group type: COMPARATOR
Intervention: Adhering to physical activity recommendations (C)
Number of subjects: 119
Study 35889944 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP-her intervention (four lifestyle sessions)
Number of subjects: 228
Study 35889944 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control)
Number of subjects: 228
Study 34781221 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Swallowing Therapy (TST) and Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 37
Study 34781221 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Swallowing Therapy (TST) and Kinesiology Taping (KT)
Number of subjects: 37
Study 34781221 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Swallowing Therapy (TST), Neuromuscular Electrical Stimulation (NMES), and Kinesiology Taping (KT)
Number of subjects: 37
Study 32521473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity pelvic model
Number of subjects: 75
Study 32521473 — intervention group
Group type: COMPARATOR
Intervention: High-fidelity computer-based mannequin
Number of subjects: 75
Study 35392979 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive Case Detection (RCD)
Number of subjects: 48
Study 35392979 — intervention group
Group type: EXPERIMENTAL
Intervention: targeted Mass Drug Administration (tMDA)
Number of subjects: 48
Study 35392979 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 48
Study 34091276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 100
Study 34091276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CPT and Cognitive Symptom Management and Rehabilitation Therapy (SMART-CPT)
Number of subjects: 100
Study 34091276 — intervention group
Group type: COMPARATOR
Intervention: CPT and SMART-CPT
Number of subjects: 100
Study 36343979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose (FDI)
Number of subjects: 97
Study 36343979 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 97
Study 36343979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FDI and FCM
Number of subjects: 97
Study 32985396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group activity with Paro (robotic seal) for 30 minutes twice a week over 12 weeks
Number of subjects: 60
Study 32985396 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control group)
Number of subjects: 60
Study 35062832 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (Resistance Training)
Number of subjects: 105
Study 35062832 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+BFR (Resistance Training with Blood Flow Restriction)
Number of subjects: 105
Study 35062832 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 33242153 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated manikin feedback
Number of subjects: 56
Study 33242153 — intervention group
Group type: COMPARATOR
Intervention: Instructor feedback
Number of subjects: 56
Study 32621874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for the first month, followed by 2000 IU daily)
Number of subjects: 4000
Study 32621874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 32621874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 4000
Study 36484691 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response Cognitive Behavioral Therapy for Chronic Pain (IVR CBT-CP)
Number of subjects: 108
Study 35322340 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (n=13)
Number of subjects: 26
Study 35322340 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=13)
Number of subjects: 26
Study 32669943 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart review (gold standard definition of recurrence)
Number of subjects: 200
Study 32669943 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition of recurrence: 2 or more cancer diagnosis codes 10 or more months from the diagnosis date
Number of subjects: 200
Study 35343942 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus ESHAP
Number of subjects: 150
Study 35343942 — intervention group
Group type: COMPARATOR
Intervention: ESHAP alone
Number of subjects: 150
Study 35343942 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 150
Study 33637350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit intervention with gamification and social support
Number of subjects: 24
Study 33637350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit intervention
Number of subjects: 24
Study 33032770 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at weeks 0, 4, and 12, and every 8 weeks thereafter
Number of subjects: 208
Study 33032770 — intervention group
Group type: COMPARATOR
Intervention: Placebo at weeks 0, 4, and 12
Number of subjects: 208
Study 36287604 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital SDM intervention for 6 months
Number of subjects: 194
Study 36287604 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 194
Study 34492632 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Early Palliative Care (EPC)
Number of subjects: 116
Study 34492632 — intervention group
Group type: COMPARATOR
Intervention: No Early Palliative Care (EPC)
Number of subjects: 116
Study 34492632 — intervention group
Group type: COMPARATOR
Intervention: Screen-negative patients
Number of subjects: 116
Study 32641967 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago ovata mucilage eye drop, 4 times a day for 6 weeks
Number of subjects: 60
Study 32641967 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drop, 4 times a day for 6 weeks
Number of subjects: 60
Study 32641967 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago ovata mucilage eye drop
Number of subjects: 60
Study 32641967 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drop
Number of subjects: 60
Study 36184697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (3-24 mg) and Reslizumab (0.1-0.8 mg/kg)
Number of subjects: 72
Study 36184697 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based simulations
Number of subjects: 72
Study 34751628 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended blood pressure measurement (121.7/68.6 mmHg)
Number of subjects: 62
Study 34751628 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended blood pressure measurement
Number of subjects: 62
Study 34751628 — intervention group
Group type: COMPARATOR
Intervention: Attended blood pressure measurement
Number of subjects: 62
Study 35345367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of 85% TCA (n=26)
Number of subjects: 53
Study 35345367 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice application of 85% TCA (n=27)
Number of subjects: 53
Study 36161779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 505
Study 34098394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block (QLB) combined with local infiltration analgesia (LIA)
Number of subjects: 80
Study 34098394 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 80
Study 32584285 — intervention group
Group type: EXPERIMENTAL
Intervention: 660-nm diode laser applied for 2 minutes
Number of subjects: 50
Study 32584285 — intervention group
Group type: COMPARATOR
Intervention: No application of 660-nm diode laser
Number of subjects: 50
Study 36181056 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids at 1500 mg per day for 3 days before and 2 days after the procedure
Number of subjects: 60
Study 36181056 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 60
Study 36181056 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 36181056 — intervention group
Group type: COMPARATOR
Intervention: Curcuminoids and Control (placebo)
Number of subjects: 60
Study 34143568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala colouring for 30 min/day for six consecutive days
Number of subjects: 70
Study 34143568 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 70
Study 35072422 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrown group
Number of subjects: 670
Study 35072422 — intervention group
Group type: COMPARATOR
Intervention: Post and core crown group
Number of subjects: 670
Study 33821899 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg orally daily for 3 years)
Number of subjects: 2526
Study 33821899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2526
Study 33821899 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2526
Study 36217848 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (2nd dose)
Number of subjects: 0
Study 32928161 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min Football activity
Number of subjects: 36
Study 32928161 — intervention group
Group type: COMPARATOR
Intervention: 60-min seated rest
Number of subjects: 36
Study 33740090 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation
Number of subjects: 0
Study 33740090 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 33153434 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary feeding behavior change communication delivered through women development army leaders for 9 months
Number of subjects: 16
Study 33153434 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (Control)
Number of subjects: 16
Study 36372995 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PIVCs
Number of subjects: 1759
Study 36372995 — intervention group
Group type: COMPARATOR
Intervention: Nonintegrated PIVCs
Number of subjects: 1759
Study 33421560 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue disinfection with povidone-iodine solution
Number of subjects: 108
Study 33421560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional disinfection)
Number of subjects: 108
Study 33421560 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous disinfection protocol
Number of subjects: 108
Study 32020438 — intervention group
Group type: EXPERIMENTAL
Intervention: SEQ tremelimumab 75 mg IV over 1 h followed by durvalumab 1500 mg IV over 1 h q4wks
Number of subjects: 14
Study 32020438 — intervention group
Group type: COMPARATOR
Intervention: CON administration of durvalumab and tremelimumab over 1 h
Number of subjects: 14
Study 32020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SEQ and CON
Number of subjects: 14
Study 35753884 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SMa)
Number of subjects: 26
Study 35753884 — intervention group
Group type: COMPARATOR
Intervention: Spinal Mobilization (SMo)
Number of subjects: 26
Study 34847581 — intervention group
Group type: EXPERIMENTAL
Intervention: Manufacturer first-fit (FF)
Number of subjects: 15
Study 34847581 — intervention group
Group type: COMPARATOR
Intervention: Aided sound-field thresholds (ASFT)
Number of subjects: 15
Study 34847581 — intervention group
Group type: COMPARATOR
Intervention: Skull simulator/DSL-BCD
Number of subjects: 15
Study 35788774 — intervention group
Group type: COMPARATOR
Intervention: Short-interval group
Number of subjects: 141
Study 35788774 — intervention group
Group type: COMPARATOR
Intervention: Long-interval group
Number of subjects: 141
Study 33009066 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA/EMDA (n = 30)
Number of subjects: 60
Study 33009066 — intervention group
Group type: COMPARATOR
Intervention: Intrasphincteric BoNTA injection (n = 30)
Number of subjects: 60
Study 36048997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 80
Study 36048997 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 80
Study 36048997 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 36048997 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 80
Study 33480241 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM (1.5, 3.0 and 6.0 g/kg)
Number of subjects: 72